Alan Musso
Director of Finance/CFO presso FULCRUM THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Manuel Alves Aivado | M | 53 | 10 anni | |
| Robert Gould | M | 69 | - | |
| Paul Romness | M | 57 |
OS Therapies, Inc.
 OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 6 anni |
| Brian Windsor | M | 57 | 1 anni | |
| Alex Sapir | M | 57 | 1 anni | |
| Richard Fair | M | 55 | 7 anni | |
| Kathryn Haviland | F | 48 | 6 anni | |
| Charles T. Garner | M | 48 | 1 anni | |
| Josef H. Von Rickenbach | M | 68 | 5 anni | |
| David Annis | M | 51 | 17 anni | |
| Katina Dorton | F | 66 | 4 anni | |
| Sonja L. Banks | F | 55 | 3 anni | |
| Mel Hayes | M | 54 | 3 anni | |
| Liz Melone | F | - | - | |
| James Geraghty | M | 70 | 8 anni | |
| William Fairey | M | 59 | 1 anni | |
| Reinhard Ambros | M | 67 | 11 anni | |
| R. Alan B. Ezekowitz | M | 70 | 8 anni | |
| James Collins | M | 58 | 7 anni | |
| Leslie Leinwand | M | - | - | |
| Iain Fraser | M | - | 1 anni | |
| Kim Hazen | F | - | 7 anni | |
| Joacim Borg | M | 32 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 2 anni |
| Curtis Oltmans | M | 60 | 4 anni | |
| John Ciccio | M | 43 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 4 anni |
| Jeffrey W. Jacobs | M | 61 | 2 anni | |
| Colin Goddard | M | 64 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 4 anni |
| Theodore F. Search | M | 42 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 4 anni |
| Robert G. Petit | M | 64 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 5 anni |
| Gregory Tourangeau | M | - | 2 anni | |
| Jenny Chaplin | F | - | 6 anni | |
| Paul Bruno | M | - | 5 anni | |
| Dee Smith | M | - | - | |
| Jack Doll | M | - |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | - |
| Kristina Storey | F | - | 2 anni | |
| Mani Sundararajan | M | - | 3 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Joseph deBethizy | M | 74 |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 15 anni |
| Kevin M. Slawin | M | 63 | 13 anni | |
| John P. Richard | M | 66 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 13 anni |
| Stephen Hill | M | 65 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 3 anni |
| Thomas J. Farrell | M | 60 | 11 anni | |
| Jon Stonehouse | M | 63 | 10 anni | |
| John Josey | M | 63 | 8 anni | |
| Mark B. Skaletsky | M | 75 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 12 anni |
| G. Steven Burrill | M | 79 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 13 anni |
| Michael Barrett | M | 81 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 anni |
| Alan K. Smith | M | 68 | 5 anni | |
| Edmund Harrigan | M | 71 | 1 anni | |
| Julia Brown | F | 76 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | - |
| Peter A. Zorn | M | 53 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 10 anni |
| James Daly | M | 63 | 8 anni | |
| Jeffrey Bailey | M | 62 | 5 anni | |
| Steven M. Toler | M | 63 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 anni |
| Shane Ward | M | 49 | 2 anni | |
| Thilo Schroeder | M | 42 | 5 anni | |
| Susan Drexler | F | 54 | 2 anni | |
| Jodie Morrison | F | 48 | 6 anni | |
| Annemarie B. Moseley | M | 68 | 6 anni | |
| Nolan Sigal | M | 73 | 5 anni | |
| Ralph Snyderman | M | 84 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 6 anni |
| Geoffrey C. Dunbar | M | 77 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 anni |
| Errol de Souza | M | 70 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 anni |
| Alan Dunton | M | 70 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 9 anni |
| John Moore | M | 59 | 1 anni | |
| William McKee | M | 62 | 4 anni | |
| Patrick C. Rock | M | 64 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | - |
| Stephen Davis | M | 63 | 9 anni | |
| Chu Shan Chen | M | 42 |
Thunderbird School of Global Management
| 2 anni |
| Shawn F. Flaherty | M | - |
St. Mary's College of California
| 4 anni |
| John E. Donahue | M | - |
St. Mary's College of California
| 5 anni |
| Mark J. Madgett | M | 62 |
St. Mary's College of California
| 4 anni |
| Steven Neeley | M | - |
Thunderbird School of Global Management
| 3 anni |
| Steven J. Winick | M | - | - | |
| Mark Steed | M | - |
Thunderbird School of Global Management
| 1 anni |
| William Grossman | M | 54 | 1 anni | |
| Joseph Woodard | M | 58 | 2 anni | |
| Jaa Roberson | F | - | 2 anni | |
| Romi S Dhillon | M | - |
Thunderbird School of Global Management
| 1 anni |
| Kelly Mullaney Dean | F | - |
St. Mary's College of California
| 4 anni |
| Hong Ma | M | 54 | 2 anni | |
| William R. Sellers | M | 63 | 2 anni | |
| Joel Montgomery | M | - |
Thunderbird School of Global Management
| 2 anni |
| James O'Malley | M | - |
Thunderbird School of Global Management
| 2 anni |
| Nancy Reggio | F | - |
St. Mary's College of California
| 4 anni |
| Eric H. Miscoll | M | 61 |
St. Mary's College of California
| 4 anni |
| Jeffrey P. Brennan | M | 66 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 10 anni |
| Don Evenson | M | - |
St. Mary's College of California
| 4 anni |
| Earl E. Sands | M | 66 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 1 anni |
| Gregory S. Naeve | M | 60 | 2 anni | |
| Micheline Bouchard | F | 76 |
Thunderbird School of Global Management
| 5 anni |
| Richard Alexander Lewis | M | - |
St. Mary's College of California
| 1 anni |
| Shang Ting Huang | F | - |
Thunderbird School of Global Management
| 2 anni |
| Charles B. Conner | M | - |
Thunderbird School of Global Management
| 1 anni |
| Scott N. Cullison | M | - | 3 anni | |
| Tim Coughlin | M | 57 | - | |
| Allie Burns | F | - |
Thunderbird School of Global Management
| 2 anni |
| Frank Scardena | M | - |
Thunderbird School of Global Management
| 2 anni |
| Tom Siino | M | - |
St. Mary's College of California
| 4 anni |
| Stefan Michel | M | 56 |
Thunderbird School of Global Management
| 5 anni |
| Steve Clegg | M | - |
Thunderbird School of Global Management
| 1 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Alan Musso
- Contatti personali
